There are 3161 resources available
Invited Discussant LBA56, LBA57 and 1259MO
Presenter: Sai-Hong Ou
Session: Mini oral session: NSCLC metastatic
Resources:
Slides
Webcast
LBA16 - Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
Presenter: Katia Khoury
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
LBA17 - Survival outcome of neoadjuvant endocrine therapy + trastuzumab and pertuzumab (ET+T+P) vs. de-escalated chemotherapy (CT)+T+P in hormone receptor positive (HR+)/HER2+ early breast cancer (EBC): WSG-TP-II trial
Presenter: Oleg Gluz
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
239MO - TILs and overall survival (OS) in HER2+ early breast cancer (eBC): 10-year (yr) updated analysis of the ShortHER trial
Presenter: Maria Vittoria Dieci
Session: Mini oral session: Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA15, LBA16, LBA17 and 239MO
Presenter: Fatima Cardoso
Session: Mini oral session: Breast cancer, early stage
Resources:
Slides
Webcast
Should we try immunotherapy for all patients with advanced cancer? - Yes
Presenter: Myriam Chalabi
Session: YO Boxing session
Resources:
Slides
Webcast
Presentation by Expert
Presenter: James Larkin
Session: How to optimally counsel my melanoma patients for adjuvant therapy
Resources:
Slides
Webcast
1435P - Immunomodulatory effects and improved survival of PG2 plus preoperative chemoradiotherapy in patients with locally advanced esophageal cancer
Presenter: Lai-Man Mok
Session: Poster session 18
Presentation by Expert
Presenter: Trevor Graham
Session: Pharmacologically manipulating evolution
Resources:
Webcast